Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 2/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.32 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.32 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.32 |
| ▸ | ITGAL | P20701 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17426095 | 0.91 | ABCG2 (0.38) | ABCG2DRD1CYP3A4TDP1PKM | |
| SCHEMBL3132985 | 0.89 | ITGB2 (0.46) | ABCG2DRD1CYP3A4TDP1PKM | |
| SCHEMBL4837678 | 0.86 | DRD1 (0.38) | ABCG2DRD1CYP3A4TDP1ESR1 | |
| SCHEMBL3136613 | 0.86 | ITGB2 (0.39) | ABCG2DRD1CYP3A4TDP1ESR1 | |
| SCHEMBL372145 | 0.86 | ITGB2 (0.39) | ABCG2DRD1CYP3A4TDP1ESR1 | |
| SCHEMBL13243539 | 0.84 | ITGB2 (0.38) | DRD1CYP3A4TDP1ITGB2ICAM1 | |
| SCHEMBL20351197 | 0.84 | ITGB2 (0.38) | DRD1CYP3A4TDP1ITGB2ICAM1 | |
| SCHEMBL3133241 | 0.84 | ITGB2 (0.38) | DRD1CYP3A4TDP1ITGB2ICAM1 | |
| SCHEMBL29352284 | 0.79 | ABCG2 (0.39) | ABCG2DRD1CYP3A4TDP1PKM | |
| SCHEMBL2076685 | 0.79 | ABCG2 (0.39) | ABCG2DRD1CYP3A4TDP1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11530230-B2 | Compound of 3,3,3′,3′-tetramethyl-1,1′-spirobiindane-based phosphine ligand, and preparation method thereof | ZHEJIANG UNIVERSITY (CN) | 2022-12-20 | — | — | US | disclosed |
| US-20210253584-A1 | Processes for Preparing Jak Inhibitors and Related Intermediate Compounds | INCYTE HOLDINGS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20210163514-A1 | COMPOUND OF 3,3,3',3'-TETRAMETHYL-1,1'-SPIROBIINDANE-BASED PHOSPHINE LIGAND, AND PREPARATION METHOD THEREOF | ZHEJIANG UNIVERSITY (CN) | 2021-06-03 | — | — | US | disclosed |
| US-10975085-B2 | Process for preparing a composition comprising an enantiomeric excess of greater than or equal to 90% of the (R)-enantiomer of a compound of formula III | INCYTE HOLDINGS CORPORATION (US) | 2021-04-13 | — | — | US | disclosed |
| US-10364248-B2 | Processes for preparing 4-chloro-7H-pyrrolo[2,3-d]pyrimidine | INCYTE CORPORATION (US) | 2019-07-30 | — | — | US | disclosed |
| US-9908888-B2 | Processes for preparing pyrazolyl-substituted pyrrolo[2,3-d]pyrimidines | INCYTE CORPORATION (US) | 2018-03-06 | — | — | US | disclosed |
| US-9908888-B2 | Processes for preparing pyrazolyl-substituted pyrrolo[2,3-d]pyrimidines | INCYTE CORPORATION (US) | 2018-03-06 | — | — | US | disclosed |
| EP-3272738-A2 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | Incyte Holdings Corporation (US) | 2018-01-24 | — | — | EP | disclosed |
| EP-2398774-B1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE HOLDINGS CORP (US) | 2017-07-05 | — | — | EP | disclosed |
| US-20170173572-A1 | CHIRAL LIGAND-BASED METAL-ORGANIC FRAMEWORKS FOR BROAD-SCOPE ASYMMETRIC CATALYSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-06-22 | — | — | US | disclosed |
| US-7541474-B2 | Catalyzed process of making C-5-substituted heterocyclic inhibitors of 11β-hydroxy steroid dehydrogenase type 1 | AMGEN INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-7541474-B2 | Catalyzed process of making C-5-substituted heterocyclic inhibitors of 11β-hydroxy steroid dehydrogenase type 1 | AMGEN INC. (US) | 2009-06-02 | — | — | US | disclosed |
| WO-2008131932-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE ETHENYLPHENYL ALCOHOLS | LONZA AG (CH) | 2008-11-06 | — | — | WO | disclosed |
| EP-1988079-A1 | Process for the preparation of optically active ethenylphenyl-alcohols | LONZA AG (CH) | 2008-11-05 | — | — | EP | disclosed |
| WO-2008077560-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE 2-AMINO-1-PHENYLETHANOLS | LONZA AG (CH) | 2008-07-03 | — | — | WO | disclosed |
| WO-2007061600-A1 | CATALYZED PROCESS OF MAKING C-5-SUBSTITUTED HETEROCYCLIC INHIBITORS OF 11ß-HYDROXY STEROID DEHYDROGENASE TYPE 1 | AMGEN, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070123492-A1 | Analogs of lysophosphatidic acid and methods of making and using thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-05-31 | — | — | US | disclosed |
| US-20070117985-A1 | Catalyzed process of making C-5-substituted heterocyclic inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 | AMGEN, INC. | 2007-05-24 | — | — | US | disclosed |
| US-7214813-B2 | Preparation of chiral cyclic amino acids and derivatives | THE PENN STATE RESEARCH FOUNDATION (US) | 2007-05-08 | — | — | US | disclosed |
| US-20050288257-A1 | Novel stable compositions of water and oxygen sensitive compounds and their method of preparation | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170173572-A1 | CHIRAL LIGAND-BASED METAL-ORGANIC FRAMEWORKS FOR BROAD-SCOPE ASYMMETRIC CATALYSIS | POF1B, FGFR1, COASY | ABCG2 1252/4885DRD1 2153/4885CYP3A4 1057/4885 |
| US-10975085-B2 | Process for preparing a composition comprising an enantiomeric excess of greater than or equal to 90% of the (R)-enantiomer of a compound of formula III | JAK1, JAK3, JAK2 | ABCG2 3302/4885DRD1 4303/4885CYP3A4 586/4885 |
| US-20210253584-A1 | Processes for Preparing Jak Inhibitors and Related Intermediate Compounds | JAK3, JAK1, JAK2 | ABCG2 2224/4885DRD1 3110/4885CYP3A4 1108/4885 |
| US-20050288257-A1 | Novel stable compositions of water and oxygen sensitive compounds and their method of preparation | COXFA4L2, CYP2F1, ABCG2 | ABCG2 3/4885DRD1 1816/4885CYP3A4 57/4885 |
| US-10364248-B2 | Processes for preparing 4-chloro-7H-pyrrolo[2,3-d]pyrimidine | JAK1, JAK3, JAK2 | ABCG2 2272/4885DRD1 2370/4885CYP3A4 823/4885 |
| US-11530230-B2 | Compound of 3,3,3′,3′-tetramethyl-1,1′-spirobiindane-based phosphine ligand, and preparation method thereof | ORMDL3, TALDO1, TAC3 | ABCG2 170/4885DRD1 271/4885CYP3A4 1674/4885 |
| US-20070117985-A1 | Catalyzed process of making C-5-substituted heterocyclic inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 | SRD5A1, HSD11B1, HSD3B1 | ABCG2 1802/4885DRD1 407/4885CYP3A4 98/4885 |
| US-20070123492-A1 | Analogs of lysophosphatidic acid and methods of making and using thereof | LPAR4, LPAR2, LPAR5 | ABCG2 3465/4885DRD1 4853/4885CYP3A4 4624/4885 |
| US-20210163514-A1 | COMPOUND OF 3,3,3',3'-TETRAMETHYL-1,1'-SPIROBIINDANE-BASED PHOSPHINE LIGAND, AND PREPARATION METHOD THEREOF | ORMDL3, TALDO1, TAC3 | ABCG2 160/4885DRD1 265/4885CYP3A4 1623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.